Physician profile
Christopher B Estopinal
NPI 1760778401
$1,295.75
in general payments reported to CMS, 2019-2025
21 companies · $168 in 2025
The $168 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $375 · 2021: $112 · 2022: $32.67 · 2023: $272 · 2024: $336 · 2025: $168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $776.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $775.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $247.76 | 2019-2025 | Clareon, Centurion, Tryptyr |
| Glaukos Corporation | $233.62 | 2023-2025 | Photrexa, Ce-Marked Kxla System, Photrexa Viscous and Photrexa |
| Omeros Corporation | $162.55 | 2019 | |
| Ocular Therapeutix, INC. | $141.97 | 2021-2024 | Dextenza |
| Sun Pharmaceutical Industries INC. | $122.65 | 2019-2025 | Cequa |
| Oyster Point Pharma, INC. | $56.87 | 2023-2024 | Tyrvaya |
| Thea Pharma INC. | $45.18 | 2024-2025 | Iyuzeh |
| Notal Vision, INC. | $44.79 | 2025 | Foresee Home |
| Rxsight INC | $33.04 | 2023 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Light Adjustable Lens (Rxlal) |
| Regeneron Healthcare Solutions, INC. | $25.91 | 2024 | Eylea Hd |
| Harrow Eye, LLC | $21.33 | 2025 | |
| Biotissue Holdings INC. | $20.22 | 2023 | |
| Dompe US, INC. | $18.71 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $17.15 | 2019 | |
| Novartis Pharmaceuticals Corporation | $16.98 | 2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $16.84 | 2023 | Tepezza |
| Allergan, INC. | $15.31 | 2021 | |
| Mallinckrodt Hospital Products INC. | $14.80 | 2021 | |
| Tearlab Corp | $14.52 | 2024 | Scoutpro Osmolarity System |
| Abbvie INC. | $14.07 | 2023 | |
| Aerie Pharmaceuticals, INC. | $11.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Estopinal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.